Skip to content

US · ABVC · BIOTECHNOLOGY

ABVC BioPharma, Inc. (ABVC) intrinsic value and stock valuation

$0.87as of 2026-11-21 · Mkt cap 14.64M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ABVC BioPharma, Inc. DCF and intrinsic value

InvestorsCraft values ABVC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ABVC’s statements →

ABVC BioPharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Fremont, CA 94538 abvcpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-7.91M
20112025
Free cash flow
-$-2.99M
20112025
Total equity
$13.3M+18% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$510K$150K$970K$360K
Operating income-$-7.15M-$-4.71M-$-6.77M-$-15.11M-$-11.71M
Net income-$-7.91M-$-4.9M-$-7.79M-$-16.42M-$-12.84M
EPSd-$-340.07K-$-419.88K-$-1.79M-$-5.18M-$-5.12M
Operating cash flow-$-2.99M-$-1.81M-$-4.19M-$-7.4M-$-7.6M
Capital expenditure$0.00$0.00-$-20K-$-120K-$-20K
Free cash flow-$-2.99M-$-1.81M-$-4.21M-$-7.52M-$-7.62M
Total assets$21.1M$7.54M$7.78M$10.9M$13.7M
Total debt$3.47M$3.2M$2.77M$3.41M$3.34M
Net debt$2.79M$2.34M$2.05M$2.02M-$-2.49M
Total equity$13.3M$720K$1.25M$4.59M$8.87M
Cash and short-term investments$750K$930K$800K$1.47M$5.94M
Income statement
20252024202320222021
Revenue$0.00$510K$150K$970K$360K
Cost of revenue$0.00$0.00$300K$290K$10K
Gross profit$0.00$510K-$-150K$680K$350K
Research and development expenses$120K$180K$1.06M$2.69M$1M
Selling, general and administrative expenses$7.03M$5.03M$5.55M$13.1M$11.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$7.15M$5.21M$6.62M$15.8M$12.1M
Cost and expenses$7.15M$5.21M$6.92M$16.1M$12.1M
Interest income$170K$90K$190K$190K$40K
Interest expense$420K$830K$1.31M$290K$230K
Depreciation and amortization$500K$200K$380K$20K$10K
Ebitda-$-7.43M-$-4.34M-$-6.33M-$-15.2M-$-10.97M
Operating income-$-7.15M-$-4.71M-$-6.77M-$-15.11M-$-11.71M
Total other income/expenses, net-$-1.2M-$-660K-$-1.26M-$-400K$500K
Income before tax-$-8.35M-$-5.37M-$-8.02M-$-15.51M-$-11.21M
Income tax expense$20K-$-110K$260K$800K$830K
Net income-$-7.91M-$-4.9M-$-7.79M-$-16.42M-$-12.84M
Weighted average shares outstanding$23.3M$11.7M$4.34M$3.17M$2.51M
Weighted average diluted shares outstanding$23.3M$11.7M$4.34M$3.17M$2.51M
Balance sheet
20252024202320222021
Cash and short-term investments$750K$930K$800K$1.47M$5.94M
Net receivables$760K$1.16M$760K$1.37M$430K
Inventory$0.00$0.00$0.00$0.00$30K
Total current assets$2.5M$2.18M$1.66M$2.99M$7.65M
Property, plant and equipment, net$14.8M$1.15M$1.38M$1.74M$2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.88M$2.26M$2.64M$3.06M$930K
Total non-current assets$18.6M$5.36M$6.13M$7.95M$6.04M
Total assets$21.1M$7.54M$7.78M$10.9M$13.7M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$1.87M$2.97M$2.36M$2.62M$2.21M
Deferred revenue$0.00$80K$80K$10K$0.00
Total current liabilities$6.16M$6.56M$6.1M$5.54M$3.69M
Long-term debt$1.6M$240K$410K$790K$1.12M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.6M$260K$430K$800K$1.14M
Capital lease obligations$0.00$240K$410K$790K$1.47M
Total liabilities$7.76M$6.82M$6.53M$6.34M$4.83M
Common stock$30K$10K$10K$0.00$30K
Retained earnings-$-76.86M-$-68.95M-$-64.05M-$-54.9M-$-38.48M
Accumulated other comprehensive income (loss)$490K$480K$520K$520K-$-1.72M
Total equity$13.3M$720K$1.25M$4.59M$8.87M
Total investments$1.94M$2.32M$2.72M$3.14M$1.04M
Total debt$3.47M$3.2M$2.77M$3.41M$3.34M
Net debt$2.79M$2.34M$2.05M$2.02M-$-2.49M
Cash flow statement
20252024202320222021
Net income-$-8.38M-$-5.26M-$-7.79M-$-16.31M-$-12.04M
Depreciation and amortization$500K$200K$380K$20K$10K
Stock-based compensation$4.14M$2.77M$190K$7.04M$5.31M
Change in working capital-$-620K-$-410K$310K$640K-$-1.61M
Accounts receivable-$-140K-$-290K$230K-$-610K-$-120K
Inventory-$-10K$0.00$0.00$30K-$-30K
Accounts payable$0.00$0.00$0.00$0.00-$-20K
Net cash provided by operating activities-$-2.99M-$-1.81M-$-4.19M-$-7.4M-$-7.6M
Investments in property, plant and equipment$0.00$0.00-$-20K-$-120K-$-20K
Acquisitions, net$0.00$0.00$0.00-$-1.6M-$-680K
Net cash used for investing activities-$-1.21M$0.00-$-360K-$-1.72M-$-810K
Common stock issued$4.3M$30K$0.00$3.66M$11.1M
Common stock repurchased$0.00-$-10K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.64M$1.98M$3.87M$4.01M$10M
Net change in cash$460K$150K-$-670K-$-5.17M$1.56M
Cash at end of period$1.33M$860K$720K$1.39M$6.57M
Operating cash flow-$-2.99M-$-1.81M-$-4.19M-$-7.4M-$-7.6M
Capital expenditure$0.00$0.00-$-20K-$-120K-$-20K
Free cash flow-$-2.99M-$-1.81M-$-4.21M-$-7.52M-$-7.62M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ABVC BioPharma, Inc.

        ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

        CEO
        Uttam Yashwant Patil
        Employees
        18
        Beta
        0.54

        Explore

        Frequently asked questions

        What is the intrinsic value of ABVC BioPharma, Inc. (ABVC)?

        InvestorsCraft does not currently publish an intrinsic value for ABVC. How the IC value is calculated.

        Is ABVC undervalued?

        InvestorsCraft does not publish an undervaluation signal for ABVC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.